Neoadjuvant chemotherapy in breast cancers
1Department of Pathology and Laboratory Medicine, University of Florida College of Medicine-Jacksonville, Jacksonville, FL, USA Shahla.Masood@jax.ufl.edu.
Women'S Health (London, England)
|November 26, 2016
Summary
Neoadjuvant chemotherapy for breast cancer can improve patient outcomes. Assessing the response to this treatment is crucial for selecting patients and managing their care effectively.
Area of Science:
- Oncology
- Surgical Oncology
- Medical Innovations
Background:
- Neoadjuvant chemotherapy is increasingly utilized in breast cancer management.
- It is offered for locally advanced disease or to facilitate breast-conserving surgery.
- Complete pathologic response after neoadjuvant chemotherapy correlates with improved patient outcomes.
Purpose of the Study:
- To highlight the significance of neoadjuvant chemotherapy in breast cancer treatment.
- To emphasize the importance of assessing treatment response.
- To discuss the impact of response assessment on patient management and outcomes.
Main Methods:
- Review of current clinical practices and evidence regarding neoadjuvant chemotherapy.
- Analysis of the relationship between treatment response and patient outcomes.
- Discussion of the role of response assessment in clinical decision-making.
Main Results:
- Neoadjuvant chemotherapy is a key strategy in managing specific breast cancer patient groups.
- Complete pathologic response is a strong predictor of favorable patient outcomes.
- The degree of response significantly influences treatment selection and follow-up.
Conclusions:
- Accurate assessment of neoadjuvant chemotherapy response is vital for optimizing breast cancer patient care.
- Response evaluation impacts patient selection, treatment adjustments, and prognosis.
- Innovations in chemotherapy and response assessment are advancing breast cancer management.
More Related Videos
15:04Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation
Published on: January 19, 2019
12.9K
04:04Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
11.1K
Related Concept Videos
01:28Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
710
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
710
01:27Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
759
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
759
01:29Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists
1.0K
Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
Phenothiazines, such as prochlorperazine...
1.0K
02:49Cancer Therapies
10.5K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
10.5K
02:56Treatment Resistant Cancers
3.9K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K
01:21Chemotherapy-Induced Nausea and Vomiting: Cannabinoids
884
Tetrahydrocannabinol (THC) is a phytocannabinoid that primarily interacts with the CB1 receptor, a type of G protein-coupled receptor (GPCR) predominantly in and around the chemoreceptor trigger zone (CTZ) and emetic center. THC also blocks the serotonin receptor activity in the dorsal vagal complex (DVC) by inhibiting serotonin release. THC exerts its anti-emetic effects through these interactions, which are beneficial for patients undergoing chemotherapy.
Two synthetic agonists of THC,...
Two synthetic agonists of THC,...
884